Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/drug-cos-lay-onus-of-medicine-approvals-at-dcgi-door-step-15084/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/drug-cos-lay-onus-of-medicine-approvals-at-dcgi-door-step-15084/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/drug-cos-lay-onus-of-medicine-approvals-at-dcgi-door-step-15084/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/drug-cos-lay-onus-of-medicine-approvals-at-dcgi-door-step-15084/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr68045f738a1ad-trace').style.display = (document.getElementById('cakeErr68045f738a1ad-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr68045f738a1ad-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr68045f738a1ad-code').style.display = (document.getElementById('cakeErr68045f738a1ad-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr68045f738a1ad-context').style.display = (document.getElementById('cakeErr68045f738a1ad-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr68045f738a1ad-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr68045f738a1ad-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 14960,
		&#039;title&#039; =&gt; &#039;Drug cos lay onus of medicine approvals at DCGI door-step&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu Business Line&lt;br /&gt;
&lt;br /&gt;
The onus of granting approvals to medicines marketed in the country is on the regulator Drug Controller General of India (DCGI), say drug companies, adding that they have adhered to the law of the land.&lt;br /&gt;
&lt;br /&gt;
The drug-makers were responding to a Parliamentary panel report on health that severely indicted the drug regulatory authority, besides alleging that &amp;ldquo;invisible hands&amp;rdquo; of drug-makers were involved in getting favourable reports on medicines before they are marketed in India.&lt;br /&gt;
&lt;br /&gt;
Bayer has conducted the mandatory clinical trials for Rivaroxaban (indicated for VTE prophylaxis) in India after getting necessary permission from the DCGI, the company said.&lt;br /&gt;
&lt;br /&gt;
The Parliamentary panel had observed: &amp;ldquo;Three opinions (from Professor of Orthopaedics, All India Institute of Medical Sciences, New Delhi; Consultant at Dayanand Medical College, Ludhiana and Professor of Orthopaedics, St. Johns Medical College, Bangalore) on rivaroxaban (Bayer) a drug for prevention of clotting are merely ditto copies of each other.&amp;rdquo;&lt;br /&gt;
&lt;br /&gt;
Bayer responded that the required data and an application for the indication was submitted to the DCGI. &amp;ldquo;As per practice, the DCGI then seeks advice from experts. Our company does not play any role in selecting these experts or evaluating their opinions. This is entirely an internal process of the DCGI. The experts send their opinion letters to the DCGI directly. The DCGI office then evaluates the experts&amp;rsquo; opinion internally,&amp;rdquo; it added.&lt;br /&gt;
&lt;br /&gt;
GlaxoSmithKline Pharmaceuticals said it had licensed Volibris (ambrisentan), a treatment for pulmonary arterial hypertension (PAH), from Gilead for marketing outside the US. Volibris was approved in Europe (2008) and US (2007), and is available in 43 countries.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;It was evaluated in 400 patients in two pivotal phase III studies, including a range of different ethnicities, to assess its safety and efficacy. The complete global clinical data set was submitted by GSK to regulatory authorities in India in 2009 and Volibris gained marketing approval in India in 2010. Since PAH is a rare disease which is life threatening and debilitating, GSK was granted a local clinical trial waiver in India,&amp;rdquo; the company said.&lt;br /&gt;
&lt;br /&gt;
Further, the company said, the Drugs &amp;amp; Cosmetics Act stated: &amp;ldquo;for drugs indicated in life threatening / serious disease or disease of special relevance to the Indian health scenario, the toxicological and clinical data requirement may be abbreviated / deferred or omitted as deemed appropriate by the licensing authority.&amp;rdquo;&lt;br /&gt;
&lt;br /&gt;
The panel report had said, GSK had not conducted the mandatory Phase III trials (involving safety and efficacy trials on patients) on the drug.&lt;br /&gt;
&lt;br /&gt;
Reacting to a similar observation on its Colistimethate and Pirfenidone by the panel, Cipla said, it followed procedures outlined by the law and there has been no violation. &amp;ldquo;As per the law, it is not mandatory to carry out Phase III trials in India for each and every new drug. Both the drugs in question are marketed in a number of countries internationally and have been proven to be life saving. We deny that there has been any collusion with the DCGI,&amp;rdquo; the company said.
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu Business Line, 11 May, 2012, http://www.thehindubusinessline.com/companies/article3407419.ece&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;drug-cos-lay-onus-of-medicine-approvals-at-dcgi-door-step-15084&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 15084,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 14960,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Drug cos lay onus of medicine approvals at DCGI door-step&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;medicines,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu Business Line

The onus of granting approvals to medicines marketed in the country is on the regulator Drug Controller General of India (DCGI), say drug companies, adding that they have adhered to the law of the land.

The drug-makers were...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu Business Line&lt;br /&gt;&lt;br /&gt;The onus of granting approvals to medicines marketed in the country is on the regulator Drug Controller General of India (DCGI), say drug companies, adding that they have adhered to the law of the land.&lt;br /&gt;&lt;br /&gt;The drug-makers were responding to a Parliamentary panel report on health that severely indicted the drug regulatory authority, besides alleging that &amp;ldquo;invisible hands&amp;rdquo; of drug-makers were involved in getting favourable reports on medicines before they are marketed in India.&lt;br /&gt;&lt;br /&gt;Bayer has conducted the mandatory clinical trials for Rivaroxaban (indicated for VTE prophylaxis) in India after getting necessary permission from the DCGI, the company said.&lt;br /&gt;&lt;br /&gt;The Parliamentary panel had observed: &amp;ldquo;Three opinions (from Professor of Orthopaedics, All India Institute of Medical Sciences, New Delhi; Consultant at Dayanand Medical College, Ludhiana and Professor of Orthopaedics, St. Johns Medical College, Bangalore) on rivaroxaban (Bayer) a drug for prevention of clotting are merely ditto copies of each other.&amp;rdquo;&lt;br /&gt;&lt;br /&gt;Bayer responded that the required data and an application for the indication was submitted to the DCGI. &amp;ldquo;As per practice, the DCGI then seeks advice from experts. Our company does not play any role in selecting these experts or evaluating their opinions. This is entirely an internal process of the DCGI. The experts send their opinion letters to the DCGI directly. The DCGI office then evaluates the experts&amp;rsquo; opinion internally,&amp;rdquo; it added.&lt;br /&gt;&lt;br /&gt;GlaxoSmithKline Pharmaceuticals said it had licensed Volibris (ambrisentan), a treatment for pulmonary arterial hypertension (PAH), from Gilead for marketing outside the US. Volibris was approved in Europe (2008) and US (2007), and is available in 43 countries.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;It was evaluated in 400 patients in two pivotal phase III studies, including a range of different ethnicities, to assess its safety and efficacy. The complete global clinical data set was submitted by GSK to regulatory authorities in India in 2009 and Volibris gained marketing approval in India in 2010. Since PAH is a rare disease which is life threatening and debilitating, GSK was granted a local clinical trial waiver in India,&amp;rdquo; the company said.&lt;br /&gt;&lt;br /&gt;Further, the company said, the Drugs &amp;amp; Cosmetics Act stated: &amp;ldquo;for drugs indicated in life threatening / serious disease or disease of special relevance to the Indian health scenario, the toxicological and clinical data requirement may be abbreviated / deferred or omitted as deemed appropriate by the licensing authority.&amp;rdquo;&lt;br /&gt;&lt;br /&gt;The panel report had said, GSK had not conducted the mandatory Phase III trials (involving safety and efficacy trials on patients) on the drug.&lt;br /&gt;&lt;br /&gt;Reacting to a similar observation on its Colistimethate and Pirfenidone by the panel, Cipla said, it followed procedures outlined by the law and there has been no violation. &amp;ldquo;As per the law, it is not mandatory to carry out Phase III trials in India for each and every new drug. Both the drugs in question are marketed in a number of countries internationally and have been proven to be life saving. We deny that there has been any collusion with the DCGI,&amp;rdquo; the company said.&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 14960,
	&#039;title&#039; =&gt; &#039;Drug cos lay onus of medicine approvals at DCGI door-step&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu Business Line&lt;br /&gt;
&lt;br /&gt;
The onus of granting approvals to medicines marketed in the country is on the regulator Drug Controller General of India (DCGI), say drug companies, adding that they have adhered to the law of the land.&lt;br /&gt;
&lt;br /&gt;
The drug-makers were responding to a Parliamentary panel report on health that severely indicted the drug regulatory authority, besides alleging that &amp;ldquo;invisible hands&amp;rdquo; of drug-makers were involved in getting favourable reports on medicines before they are marketed in India.&lt;br /&gt;
&lt;br /&gt;
Bayer has conducted the mandatory clinical trials for Rivaroxaban (indicated for VTE prophylaxis) in India after getting necessary permission from the DCGI, the company said.&lt;br /&gt;
&lt;br /&gt;
The Parliamentary panel had observed: &amp;ldquo;Three opinions (from Professor of Orthopaedics, All India Institute of Medical Sciences, New Delhi; Consultant at Dayanand Medical College, Ludhiana and Professor of Orthopaedics, St. Johns Medical College, Bangalore) on rivaroxaban (Bayer) a drug for prevention of clotting are merely ditto copies of each other.&amp;rdquo;&lt;br /&gt;
&lt;br /&gt;
Bayer responded that the required data and an application for the indication was submitted to the DCGI. &amp;ldquo;As per practice, the DCGI then seeks advice from experts. Our company does not play any role in selecting these experts or evaluating their opinions. This is entirely an internal process of the DCGI. The experts send their opinion letters to the DCGI directly. The DCGI office then evaluates the experts&amp;rsquo; opinion internally,&amp;rdquo; it added.&lt;br /&gt;
&lt;br /&gt;
GlaxoSmithKline Pharmaceuticals said it had licensed Volibris (ambrisentan), a treatment for pulmonary arterial hypertension (PAH), from Gilead for marketing outside the US. Volibris was approved in Europe (2008) and US (2007), and is available in 43 countries.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;It was evaluated in 400 patients in two pivotal phase III studies, including a range of different ethnicities, to assess its safety and efficacy. The complete global clinical data set was submitted by GSK to regulatory authorities in India in 2009 and Volibris gained marketing approval in India in 2010. Since PAH is a rare disease which is life threatening and debilitating, GSK was granted a local clinical trial waiver in India,&amp;rdquo; the company said.&lt;br /&gt;
&lt;br /&gt;
Further, the company said, the Drugs &amp;amp; Cosmetics Act stated: &amp;ldquo;for drugs indicated in life threatening / serious disease or disease of special relevance to the Indian health scenario, the toxicological and clinical data requirement may be abbreviated / deferred or omitted as deemed appropriate by the licensing authority.&amp;rdquo;&lt;br /&gt;
&lt;br /&gt;
The panel report had said, GSK had not conducted the mandatory Phase III trials (involving safety and efficacy trials on patients) on the drug.&lt;br /&gt;
&lt;br /&gt;
Reacting to a similar observation on its Colistimethate and Pirfenidone by the panel, Cipla said, it followed procedures outlined by the law and there has been no violation. &amp;ldquo;As per the law, it is not mandatory to carry out Phase III trials in India for each and every new drug. Both the drugs in question are marketed in a number of countries internationally and have been proven to be life saving. We deny that there has been any collusion with the DCGI,&amp;rdquo; the company said.
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu Business Line, 11 May, 2012, http://www.thehindubusinessline.com/companies/article3407419.ece&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;drug-cos-lay-onus-of-medicine-approvals-at-dcgi-door-step-15084&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 15084,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 14960
$metaTitle = &#039;LATEST NEWS UPDATES | Drug cos lay onus of medicine approvals at DCGI door-step&#039;
$metaKeywords = &#039;medicines,Health&#039;
$metaDesc = &#039;
-The Hindu Business Line

The onus of granting approvals to medicines marketed in the country is on the regulator Drug Controller General of India (DCGI), say drug companies, adding that they have adhered to the law of the land.

The drug-makers were...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu Business Line&lt;br /&gt;&lt;br /&gt;The onus of granting approvals to medicines marketed in the country is on the regulator Drug Controller General of India (DCGI), say drug companies, adding that they have adhered to the law of the land.&lt;br /&gt;&lt;br /&gt;The drug-makers were responding to a Parliamentary panel report on health that severely indicted the drug regulatory authority, besides alleging that &amp;ldquo;invisible hands&amp;rdquo; of drug-makers were involved in getting favourable reports on medicines before they are marketed in India.&lt;br /&gt;&lt;br /&gt;Bayer has conducted the mandatory clinical trials for Rivaroxaban (indicated for VTE prophylaxis) in India after getting necessary permission from the DCGI, the company said.&lt;br /&gt;&lt;br /&gt;The Parliamentary panel had observed: &amp;ldquo;Three opinions (from Professor of Orthopaedics, All India Institute of Medical Sciences, New Delhi; Consultant at Dayanand Medical College, Ludhiana and Professor of Orthopaedics, St. Johns Medical College, Bangalore) on rivaroxaban (Bayer) a drug for prevention of clotting are merely ditto copies of each other.&amp;rdquo;&lt;br /&gt;&lt;br /&gt;Bayer responded that the required data and an application for the indication was submitted to the DCGI. &amp;ldquo;As per practice, the DCGI then seeks advice from experts. Our company does not play any role in selecting these experts or evaluating their opinions. This is entirely an internal process of the DCGI. The experts send their opinion letters to the DCGI directly. The DCGI office then evaluates the experts&amp;rsquo; opinion internally,&amp;rdquo; it added.&lt;br /&gt;&lt;br /&gt;GlaxoSmithKline Pharmaceuticals said it had licensed Volibris (ambrisentan), a treatment for pulmonary arterial hypertension (PAH), from Gilead for marketing outside the US. Volibris was approved in Europe (2008) and US (2007), and is available in 43 countries.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;It was evaluated in 400 patients in two pivotal phase III studies, including a range of different ethnicities, to assess its safety and efficacy. The complete global clinical data set was submitted by GSK to regulatory authorities in India in 2009 and Volibris gained marketing approval in India in 2010. Since PAH is a rare disease which is life threatening and debilitating, GSK was granted a local clinical trial waiver in India,&amp;rdquo; the company said.&lt;br /&gt;&lt;br /&gt;Further, the company said, the Drugs &amp;amp; Cosmetics Act stated: &amp;ldquo;for drugs indicated in life threatening / serious disease or disease of special relevance to the Indian health scenario, the toxicological and clinical data requirement may be abbreviated / deferred or omitted as deemed appropriate by the licensing authority.&amp;rdquo;&lt;br /&gt;&lt;br /&gt;The panel report had said, GSK had not conducted the mandatory Phase III trials (involving safety and efficacy trials on patients) on the drug.&lt;br /&gt;&lt;br /&gt;Reacting to a similar observation on its Colistimethate and Pirfenidone by the panel, Cipla said, it followed procedures outlined by the law and there has been no violation. &amp;ldquo;As per the law, it is not mandatory to carry out Phase III trials in India for each and every new drug. Both the drugs in question are marketed in a number of countries internationally and have been proven to be life saving. We deny that there has been any collusion with the DCGI,&amp;rdquo; the company said.&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/drug-cos-lay-onus-of-medicine-approvals-at-dcgi-door-step-15084.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Drug cos lay onus of medicine approvals at DCGI door-step | Im4change.org</title>
    <meta name="description" content="
-The Hindu Business Line

The onus of granting approvals to medicines marketed in the country is on the regulator Drug Controller General of India (DCGI), say drug companies, adding that they have adhered to the law of the land.

The drug-makers were..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Drug cos lay onus of medicine approvals at DCGI door-step</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu Business Line<br /><br />The onus of granting approvals to medicines marketed in the country is on the regulator Drug Controller General of India (DCGI), say drug companies, adding that they have adhered to the law of the land.<br /><br />The drug-makers were responding to a Parliamentary panel report on health that severely indicted the drug regulatory authority, besides alleging that &ldquo;invisible hands&rdquo; of drug-makers were involved in getting favourable reports on medicines before they are marketed in India.<br /><br />Bayer has conducted the mandatory clinical trials for Rivaroxaban (indicated for VTE prophylaxis) in India after getting necessary permission from the DCGI, the company said.<br /><br />The Parliamentary panel had observed: &ldquo;Three opinions (from Professor of Orthopaedics, All India Institute of Medical Sciences, New Delhi; Consultant at Dayanand Medical College, Ludhiana and Professor of Orthopaedics, St. Johns Medical College, Bangalore) on rivaroxaban (Bayer) a drug for prevention of clotting are merely ditto copies of each other.&rdquo;<br /><br />Bayer responded that the required data and an application for the indication was submitted to the DCGI. &ldquo;As per practice, the DCGI then seeks advice from experts. Our company does not play any role in selecting these experts or evaluating their opinions. This is entirely an internal process of the DCGI. The experts send their opinion letters to the DCGI directly. The DCGI office then evaluates the experts&rsquo; opinion internally,&rdquo; it added.<br /><br />GlaxoSmithKline Pharmaceuticals said it had licensed Volibris (ambrisentan), a treatment for pulmonary arterial hypertension (PAH), from Gilead for marketing outside the US. Volibris was approved in Europe (2008) and US (2007), and is available in 43 countries.<br /><br />&ldquo;It was evaluated in 400 patients in two pivotal phase III studies, including a range of different ethnicities, to assess its safety and efficacy. The complete global clinical data set was submitted by GSK to regulatory authorities in India in 2009 and Volibris gained marketing approval in India in 2010. Since PAH is a rare disease which is life threatening and debilitating, GSK was granted a local clinical trial waiver in India,&rdquo; the company said.<br /><br />Further, the company said, the Drugs &amp; Cosmetics Act stated: &ldquo;for drugs indicated in life threatening / serious disease or disease of special relevance to the Indian health scenario, the toxicological and clinical data requirement may be abbreviated / deferred or omitted as deemed appropriate by the licensing authority.&rdquo;<br /><br />The panel report had said, GSK had not conducted the mandatory Phase III trials (involving safety and efficacy trials on patients) on the drug.<br /><br />Reacting to a similar observation on its Colistimethate and Pirfenidone by the panel, Cipla said, it followed procedures outlined by the law and there has been no violation. &ldquo;As per the law, it is not mandatory to carry out Phase III trials in India for each and every new drug. Both the drugs in question are marketed in a number of countries internationally and have been proven to be life saving. We deny that there has been any collusion with the DCGI,&rdquo; the company said.</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr68045f738a1ad-trace').style.display = (document.getElementById('cakeErr68045f738a1ad-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr68045f738a1ad-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr68045f738a1ad-code').style.display = (document.getElementById('cakeErr68045f738a1ad-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr68045f738a1ad-context').style.display = (document.getElementById('cakeErr68045f738a1ad-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr68045f738a1ad-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr68045f738a1ad-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 14960,
		&#039;title&#039; =&gt; &#039;Drug cos lay onus of medicine approvals at DCGI door-step&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu Business Line&lt;br /&gt;
&lt;br /&gt;
The onus of granting approvals to medicines marketed in the country is on the regulator Drug Controller General of India (DCGI), say drug companies, adding that they have adhered to the law of the land.&lt;br /&gt;
&lt;br /&gt;
The drug-makers were responding to a Parliamentary panel report on health that severely indicted the drug regulatory authority, besides alleging that &amp;ldquo;invisible hands&amp;rdquo; of drug-makers were involved in getting favourable reports on medicines before they are marketed in India.&lt;br /&gt;
&lt;br /&gt;
Bayer has conducted the mandatory clinical trials for Rivaroxaban (indicated for VTE prophylaxis) in India after getting necessary permission from the DCGI, the company said.&lt;br /&gt;
&lt;br /&gt;
The Parliamentary panel had observed: &amp;ldquo;Three opinions (from Professor of Orthopaedics, All India Institute of Medical Sciences, New Delhi; Consultant at Dayanand Medical College, Ludhiana and Professor of Orthopaedics, St. Johns Medical College, Bangalore) on rivaroxaban (Bayer) a drug for prevention of clotting are merely ditto copies of each other.&amp;rdquo;&lt;br /&gt;
&lt;br /&gt;
Bayer responded that the required data and an application for the indication was submitted to the DCGI. &amp;ldquo;As per practice, the DCGI then seeks advice from experts. Our company does not play any role in selecting these experts or evaluating their opinions. This is entirely an internal process of the DCGI. The experts send their opinion letters to the DCGI directly. The DCGI office then evaluates the experts&amp;rsquo; opinion internally,&amp;rdquo; it added.&lt;br /&gt;
&lt;br /&gt;
GlaxoSmithKline Pharmaceuticals said it had licensed Volibris (ambrisentan), a treatment for pulmonary arterial hypertension (PAH), from Gilead for marketing outside the US. Volibris was approved in Europe (2008) and US (2007), and is available in 43 countries.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;It was evaluated in 400 patients in two pivotal phase III studies, including a range of different ethnicities, to assess its safety and efficacy. The complete global clinical data set was submitted by GSK to regulatory authorities in India in 2009 and Volibris gained marketing approval in India in 2010. Since PAH is a rare disease which is life threatening and debilitating, GSK was granted a local clinical trial waiver in India,&amp;rdquo; the company said.&lt;br /&gt;
&lt;br /&gt;
Further, the company said, the Drugs &amp;amp; Cosmetics Act stated: &amp;ldquo;for drugs indicated in life threatening / serious disease or disease of special relevance to the Indian health scenario, the toxicological and clinical data requirement may be abbreviated / deferred or omitted as deemed appropriate by the licensing authority.&amp;rdquo;&lt;br /&gt;
&lt;br /&gt;
The panel report had said, GSK had not conducted the mandatory Phase III trials (involving safety and efficacy trials on patients) on the drug.&lt;br /&gt;
&lt;br /&gt;
Reacting to a similar observation on its Colistimethate and Pirfenidone by the panel, Cipla said, it followed procedures outlined by the law and there has been no violation. &amp;ldquo;As per the law, it is not mandatory to carry out Phase III trials in India for each and every new drug. Both the drugs in question are marketed in a number of countries internationally and have been proven to be life saving. We deny that there has been any collusion with the DCGI,&amp;rdquo; the company said.
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu Business Line, 11 May, 2012, http://www.thehindubusinessline.com/companies/article3407419.ece&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;drug-cos-lay-onus-of-medicine-approvals-at-dcgi-door-step-15084&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 15084,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 14960,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Drug cos lay onus of medicine approvals at DCGI door-step&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;medicines,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu Business Line

The onus of granting approvals to medicines marketed in the country is on the regulator Drug Controller General of India (DCGI), say drug companies, adding that they have adhered to the law of the land.

The drug-makers were...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu Business Line&lt;br /&gt;&lt;br /&gt;The onus of granting approvals to medicines marketed in the country is on the regulator Drug Controller General of India (DCGI), say drug companies, adding that they have adhered to the law of the land.&lt;br /&gt;&lt;br /&gt;The drug-makers were responding to a Parliamentary panel report on health that severely indicted the drug regulatory authority, besides alleging that &amp;ldquo;invisible hands&amp;rdquo; of drug-makers were involved in getting favourable reports on medicines before they are marketed in India.&lt;br /&gt;&lt;br /&gt;Bayer has conducted the mandatory clinical trials for Rivaroxaban (indicated for VTE prophylaxis) in India after getting necessary permission from the DCGI, the company said.&lt;br /&gt;&lt;br /&gt;The Parliamentary panel had observed: &amp;ldquo;Three opinions (from Professor of Orthopaedics, All India Institute of Medical Sciences, New Delhi; Consultant at Dayanand Medical College, Ludhiana and Professor of Orthopaedics, St. Johns Medical College, Bangalore) on rivaroxaban (Bayer) a drug for prevention of clotting are merely ditto copies of each other.&amp;rdquo;&lt;br /&gt;&lt;br /&gt;Bayer responded that the required data and an application for the indication was submitted to the DCGI. &amp;ldquo;As per practice, the DCGI then seeks advice from experts. Our company does not play any role in selecting these experts or evaluating their opinions. This is entirely an internal process of the DCGI. The experts send their opinion letters to the DCGI directly. The DCGI office then evaluates the experts&amp;rsquo; opinion internally,&amp;rdquo; it added.&lt;br /&gt;&lt;br /&gt;GlaxoSmithKline Pharmaceuticals said it had licensed Volibris (ambrisentan), a treatment for pulmonary arterial hypertension (PAH), from Gilead for marketing outside the US. Volibris was approved in Europe (2008) and US (2007), and is available in 43 countries.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;It was evaluated in 400 patients in two pivotal phase III studies, including a range of different ethnicities, to assess its safety and efficacy. The complete global clinical data set was submitted by GSK to regulatory authorities in India in 2009 and Volibris gained marketing approval in India in 2010. Since PAH is a rare disease which is life threatening and debilitating, GSK was granted a local clinical trial waiver in India,&amp;rdquo; the company said.&lt;br /&gt;&lt;br /&gt;Further, the company said, the Drugs &amp;amp; Cosmetics Act stated: &amp;ldquo;for drugs indicated in life threatening / serious disease or disease of special relevance to the Indian health scenario, the toxicological and clinical data requirement may be abbreviated / deferred or omitted as deemed appropriate by the licensing authority.&amp;rdquo;&lt;br /&gt;&lt;br /&gt;The panel report had said, GSK had not conducted the mandatory Phase III trials (involving safety and efficacy trials on patients) on the drug.&lt;br /&gt;&lt;br /&gt;Reacting to a similar observation on its Colistimethate and Pirfenidone by the panel, Cipla said, it followed procedures outlined by the law and there has been no violation. &amp;ldquo;As per the law, it is not mandatory to carry out Phase III trials in India for each and every new drug. Both the drugs in question are marketed in a number of countries internationally and have been proven to be life saving. We deny that there has been any collusion with the DCGI,&amp;rdquo; the company said.&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 14960,
	&#039;title&#039; =&gt; &#039;Drug cos lay onus of medicine approvals at DCGI door-step&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu Business Line&lt;br /&gt;
&lt;br /&gt;
The onus of granting approvals to medicines marketed in the country is on the regulator Drug Controller General of India (DCGI), say drug companies, adding that they have adhered to the law of the land.&lt;br /&gt;
&lt;br /&gt;
The drug-makers were responding to a Parliamentary panel report on health that severely indicted the drug regulatory authority, besides alleging that &amp;ldquo;invisible hands&amp;rdquo; of drug-makers were involved in getting favourable reports on medicines before they are marketed in India.&lt;br /&gt;
&lt;br /&gt;
Bayer has conducted the mandatory clinical trials for Rivaroxaban (indicated for VTE prophylaxis) in India after getting necessary permission from the DCGI, the company said.&lt;br /&gt;
&lt;br /&gt;
The Parliamentary panel had observed: &amp;ldquo;Three opinions (from Professor of Orthopaedics, All India Institute of Medical Sciences, New Delhi; Consultant at Dayanand Medical College, Ludhiana and Professor of Orthopaedics, St. Johns Medical College, Bangalore) on rivaroxaban (Bayer) a drug for prevention of clotting are merely ditto copies of each other.&amp;rdquo;&lt;br /&gt;
&lt;br /&gt;
Bayer responded that the required data and an application for the indication was submitted to the DCGI. &amp;ldquo;As per practice, the DCGI then seeks advice from experts. Our company does not play any role in selecting these experts or evaluating their opinions. This is entirely an internal process of the DCGI. The experts send their opinion letters to the DCGI directly. The DCGI office then evaluates the experts&amp;rsquo; opinion internally,&amp;rdquo; it added.&lt;br /&gt;
&lt;br /&gt;
GlaxoSmithKline Pharmaceuticals said it had licensed Volibris (ambrisentan), a treatment for pulmonary arterial hypertension (PAH), from Gilead for marketing outside the US. Volibris was approved in Europe (2008) and US (2007), and is available in 43 countries.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;It was evaluated in 400 patients in two pivotal phase III studies, including a range of different ethnicities, to assess its safety and efficacy. The complete global clinical data set was submitted by GSK to regulatory authorities in India in 2009 and Volibris gained marketing approval in India in 2010. Since PAH is a rare disease which is life threatening and debilitating, GSK was granted a local clinical trial waiver in India,&amp;rdquo; the company said.&lt;br /&gt;
&lt;br /&gt;
Further, the company said, the Drugs &amp;amp; Cosmetics Act stated: &amp;ldquo;for drugs indicated in life threatening / serious disease or disease of special relevance to the Indian health scenario, the toxicological and clinical data requirement may be abbreviated / deferred or omitted as deemed appropriate by the licensing authority.&amp;rdquo;&lt;br /&gt;
&lt;br /&gt;
The panel report had said, GSK had not conducted the mandatory Phase III trials (involving safety and efficacy trials on patients) on the drug.&lt;br /&gt;
&lt;br /&gt;
Reacting to a similar observation on its Colistimethate and Pirfenidone by the panel, Cipla said, it followed procedures outlined by the law and there has been no violation. &amp;ldquo;As per the law, it is not mandatory to carry out Phase III trials in India for each and every new drug. Both the drugs in question are marketed in a number of countries internationally and have been proven to be life saving. We deny that there has been any collusion with the DCGI,&amp;rdquo; the company said.
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu Business Line, 11 May, 2012, http://www.thehindubusinessline.com/companies/article3407419.ece&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;drug-cos-lay-onus-of-medicine-approvals-at-dcgi-door-step-15084&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 15084,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 14960
$metaTitle = &#039;LATEST NEWS UPDATES | Drug cos lay onus of medicine approvals at DCGI door-step&#039;
$metaKeywords = &#039;medicines,Health&#039;
$metaDesc = &#039;
-The Hindu Business Line

The onus of granting approvals to medicines marketed in the country is on the regulator Drug Controller General of India (DCGI), say drug companies, adding that they have adhered to the law of the land.

The drug-makers were...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu Business Line&lt;br /&gt;&lt;br /&gt;The onus of granting approvals to medicines marketed in the country is on the regulator Drug Controller General of India (DCGI), say drug companies, adding that they have adhered to the law of the land.&lt;br /&gt;&lt;br /&gt;The drug-makers were responding to a Parliamentary panel report on health that severely indicted the drug regulatory authority, besides alleging that &amp;ldquo;invisible hands&amp;rdquo; of drug-makers were involved in getting favourable reports on medicines before they are marketed in India.&lt;br /&gt;&lt;br /&gt;Bayer has conducted the mandatory clinical trials for Rivaroxaban (indicated for VTE prophylaxis) in India after getting necessary permission from the DCGI, the company said.&lt;br /&gt;&lt;br /&gt;The Parliamentary panel had observed: &amp;ldquo;Three opinions (from Professor of Orthopaedics, All India Institute of Medical Sciences, New Delhi; Consultant at Dayanand Medical College, Ludhiana and Professor of Orthopaedics, St. Johns Medical College, Bangalore) on rivaroxaban (Bayer) a drug for prevention of clotting are merely ditto copies of each other.&amp;rdquo;&lt;br /&gt;&lt;br /&gt;Bayer responded that the required data and an application for the indication was submitted to the DCGI. &amp;ldquo;As per practice, the DCGI then seeks advice from experts. Our company does not play any role in selecting these experts or evaluating their opinions. This is entirely an internal process of the DCGI. The experts send their opinion letters to the DCGI directly. The DCGI office then evaluates the experts&amp;rsquo; opinion internally,&amp;rdquo; it added.&lt;br /&gt;&lt;br /&gt;GlaxoSmithKline Pharmaceuticals said it had licensed Volibris (ambrisentan), a treatment for pulmonary arterial hypertension (PAH), from Gilead for marketing outside the US. Volibris was approved in Europe (2008) and US (2007), and is available in 43 countries.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;It was evaluated in 400 patients in two pivotal phase III studies, including a range of different ethnicities, to assess its safety and efficacy. The complete global clinical data set was submitted by GSK to regulatory authorities in India in 2009 and Volibris gained marketing approval in India in 2010. Since PAH is a rare disease which is life threatening and debilitating, GSK was granted a local clinical trial waiver in India,&amp;rdquo; the company said.&lt;br /&gt;&lt;br /&gt;Further, the company said, the Drugs &amp;amp; Cosmetics Act stated: &amp;ldquo;for drugs indicated in life threatening / serious disease or disease of special relevance to the Indian health scenario, the toxicological and clinical data requirement may be abbreviated / deferred or omitted as deemed appropriate by the licensing authority.&amp;rdquo;&lt;br /&gt;&lt;br /&gt;The panel report had said, GSK had not conducted the mandatory Phase III trials (involving safety and efficacy trials on patients) on the drug.&lt;br /&gt;&lt;br /&gt;Reacting to a similar observation on its Colistimethate and Pirfenidone by the panel, Cipla said, it followed procedures outlined by the law and there has been no violation. &amp;ldquo;As per the law, it is not mandatory to carry out Phase III trials in India for each and every new drug. Both the drugs in question are marketed in a number of countries internationally and have been proven to be life saving. We deny that there has been any collusion with the DCGI,&amp;rdquo; the company said.&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/drug-cos-lay-onus-of-medicine-approvals-at-dcgi-door-step-15084.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Drug cos lay onus of medicine approvals at DCGI door-step | Im4change.org</title>
    <meta name="description" content="
-The Hindu Business Line

The onus of granting approvals to medicines marketed in the country is on the regulator Drug Controller General of India (DCGI), say drug companies, adding that they have adhered to the law of the land.

The drug-makers were..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Drug cos lay onus of medicine approvals at DCGI door-step</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu Business Line<br /><br />The onus of granting approvals to medicines marketed in the country is on the regulator Drug Controller General of India (DCGI), say drug companies, adding that they have adhered to the law of the land.<br /><br />The drug-makers were responding to a Parliamentary panel report on health that severely indicted the drug regulatory authority, besides alleging that &ldquo;invisible hands&rdquo; of drug-makers were involved in getting favourable reports on medicines before they are marketed in India.<br /><br />Bayer has conducted the mandatory clinical trials for Rivaroxaban (indicated for VTE prophylaxis) in India after getting necessary permission from the DCGI, the company said.<br /><br />The Parliamentary panel had observed: &ldquo;Three opinions (from Professor of Orthopaedics, All India Institute of Medical Sciences, New Delhi; Consultant at Dayanand Medical College, Ludhiana and Professor of Orthopaedics, St. Johns Medical College, Bangalore) on rivaroxaban (Bayer) a drug for prevention of clotting are merely ditto copies of each other.&rdquo;<br /><br />Bayer responded that the required data and an application for the indication was submitted to the DCGI. &ldquo;As per practice, the DCGI then seeks advice from experts. Our company does not play any role in selecting these experts or evaluating their opinions. This is entirely an internal process of the DCGI. The experts send their opinion letters to the DCGI directly. The DCGI office then evaluates the experts&rsquo; opinion internally,&rdquo; it added.<br /><br />GlaxoSmithKline Pharmaceuticals said it had licensed Volibris (ambrisentan), a treatment for pulmonary arterial hypertension (PAH), from Gilead for marketing outside the US. Volibris was approved in Europe (2008) and US (2007), and is available in 43 countries.<br /><br />&ldquo;It was evaluated in 400 patients in two pivotal phase III studies, including a range of different ethnicities, to assess its safety and efficacy. The complete global clinical data set was submitted by GSK to regulatory authorities in India in 2009 and Volibris gained marketing approval in India in 2010. Since PAH is a rare disease which is life threatening and debilitating, GSK was granted a local clinical trial waiver in India,&rdquo; the company said.<br /><br />Further, the company said, the Drugs &amp; Cosmetics Act stated: &ldquo;for drugs indicated in life threatening / serious disease or disease of special relevance to the Indian health scenario, the toxicological and clinical data requirement may be abbreviated / deferred or omitted as deemed appropriate by the licensing authority.&rdquo;<br /><br />The panel report had said, GSK had not conducted the mandatory Phase III trials (involving safety and efficacy trials on patients) on the drug.<br /><br />Reacting to a similar observation on its Colistimethate and Pirfenidone by the panel, Cipla said, it followed procedures outlined by the law and there has been no violation. &ldquo;As per the law, it is not mandatory to carry out Phase III trials in India for each and every new drug. Both the drugs in question are marketed in a number of countries internationally and have been proven to be life saving. We deny that there has been any collusion with the DCGI,&rdquo; the company said.</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr68045f738a1ad-trace').style.display = (document.getElementById('cakeErr68045f738a1ad-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr68045f738a1ad-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr68045f738a1ad-code').style.display = (document.getElementById('cakeErr68045f738a1ad-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr68045f738a1ad-context').style.display = (document.getElementById('cakeErr68045f738a1ad-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr68045f738a1ad-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr68045f738a1ad-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 14960,
		&#039;title&#039; =&gt; &#039;Drug cos lay onus of medicine approvals at DCGI door-step&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu Business Line&lt;br /&gt;
&lt;br /&gt;
The onus of granting approvals to medicines marketed in the country is on the regulator Drug Controller General of India (DCGI), say drug companies, adding that they have adhered to the law of the land.&lt;br /&gt;
&lt;br /&gt;
The drug-makers were responding to a Parliamentary panel report on health that severely indicted the drug regulatory authority, besides alleging that &amp;ldquo;invisible hands&amp;rdquo; of drug-makers were involved in getting favourable reports on medicines before they are marketed in India.&lt;br /&gt;
&lt;br /&gt;
Bayer has conducted the mandatory clinical trials for Rivaroxaban (indicated for VTE prophylaxis) in India after getting necessary permission from the DCGI, the company said.&lt;br /&gt;
&lt;br /&gt;
The Parliamentary panel had observed: &amp;ldquo;Three opinions (from Professor of Orthopaedics, All India Institute of Medical Sciences, New Delhi; Consultant at Dayanand Medical College, Ludhiana and Professor of Orthopaedics, St. Johns Medical College, Bangalore) on rivaroxaban (Bayer) a drug for prevention of clotting are merely ditto copies of each other.&amp;rdquo;&lt;br /&gt;
&lt;br /&gt;
Bayer responded that the required data and an application for the indication was submitted to the DCGI. &amp;ldquo;As per practice, the DCGI then seeks advice from experts. Our company does not play any role in selecting these experts or evaluating their opinions. This is entirely an internal process of the DCGI. The experts send their opinion letters to the DCGI directly. The DCGI office then evaluates the experts&amp;rsquo; opinion internally,&amp;rdquo; it added.&lt;br /&gt;
&lt;br /&gt;
GlaxoSmithKline Pharmaceuticals said it had licensed Volibris (ambrisentan), a treatment for pulmonary arterial hypertension (PAH), from Gilead for marketing outside the US. Volibris was approved in Europe (2008) and US (2007), and is available in 43 countries.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;It was evaluated in 400 patients in two pivotal phase III studies, including a range of different ethnicities, to assess its safety and efficacy. The complete global clinical data set was submitted by GSK to regulatory authorities in India in 2009 and Volibris gained marketing approval in India in 2010. Since PAH is a rare disease which is life threatening and debilitating, GSK was granted a local clinical trial waiver in India,&amp;rdquo; the company said.&lt;br /&gt;
&lt;br /&gt;
Further, the company said, the Drugs &amp;amp; Cosmetics Act stated: &amp;ldquo;for drugs indicated in life threatening / serious disease or disease of special relevance to the Indian health scenario, the toxicological and clinical data requirement may be abbreviated / deferred or omitted as deemed appropriate by the licensing authority.&amp;rdquo;&lt;br /&gt;
&lt;br /&gt;
The panel report had said, GSK had not conducted the mandatory Phase III trials (involving safety and efficacy trials on patients) on the drug.&lt;br /&gt;
&lt;br /&gt;
Reacting to a similar observation on its Colistimethate and Pirfenidone by the panel, Cipla said, it followed procedures outlined by the law and there has been no violation. &amp;ldquo;As per the law, it is not mandatory to carry out Phase III trials in India for each and every new drug. Both the drugs in question are marketed in a number of countries internationally and have been proven to be life saving. We deny that there has been any collusion with the DCGI,&amp;rdquo; the company said.
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu Business Line, 11 May, 2012, http://www.thehindubusinessline.com/companies/article3407419.ece&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;drug-cos-lay-onus-of-medicine-approvals-at-dcgi-door-step-15084&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 15084,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 14960,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Drug cos lay onus of medicine approvals at DCGI door-step&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;medicines,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu Business Line

The onus of granting approvals to medicines marketed in the country is on the regulator Drug Controller General of India (DCGI), say drug companies, adding that they have adhered to the law of the land.

The drug-makers were...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu Business Line&lt;br /&gt;&lt;br /&gt;The onus of granting approvals to medicines marketed in the country is on the regulator Drug Controller General of India (DCGI), say drug companies, adding that they have adhered to the law of the land.&lt;br /&gt;&lt;br /&gt;The drug-makers were responding to a Parliamentary panel report on health that severely indicted the drug regulatory authority, besides alleging that &amp;ldquo;invisible hands&amp;rdquo; of drug-makers were involved in getting favourable reports on medicines before they are marketed in India.&lt;br /&gt;&lt;br /&gt;Bayer has conducted the mandatory clinical trials for Rivaroxaban (indicated for VTE prophylaxis) in India after getting necessary permission from the DCGI, the company said.&lt;br /&gt;&lt;br /&gt;The Parliamentary panel had observed: &amp;ldquo;Three opinions (from Professor of Orthopaedics, All India Institute of Medical Sciences, New Delhi; Consultant at Dayanand Medical College, Ludhiana and Professor of Orthopaedics, St. Johns Medical College, Bangalore) on rivaroxaban (Bayer) a drug for prevention of clotting are merely ditto copies of each other.&amp;rdquo;&lt;br /&gt;&lt;br /&gt;Bayer responded that the required data and an application for the indication was submitted to the DCGI. &amp;ldquo;As per practice, the DCGI then seeks advice from experts. Our company does not play any role in selecting these experts or evaluating their opinions. This is entirely an internal process of the DCGI. The experts send their opinion letters to the DCGI directly. The DCGI office then evaluates the experts&amp;rsquo; opinion internally,&amp;rdquo; it added.&lt;br /&gt;&lt;br /&gt;GlaxoSmithKline Pharmaceuticals said it had licensed Volibris (ambrisentan), a treatment for pulmonary arterial hypertension (PAH), from Gilead for marketing outside the US. Volibris was approved in Europe (2008) and US (2007), and is available in 43 countries.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;It was evaluated in 400 patients in two pivotal phase III studies, including a range of different ethnicities, to assess its safety and efficacy. The complete global clinical data set was submitted by GSK to regulatory authorities in India in 2009 and Volibris gained marketing approval in India in 2010. Since PAH is a rare disease which is life threatening and debilitating, GSK was granted a local clinical trial waiver in India,&amp;rdquo; the company said.&lt;br /&gt;&lt;br /&gt;Further, the company said, the Drugs &amp;amp; Cosmetics Act stated: &amp;ldquo;for drugs indicated in life threatening / serious disease or disease of special relevance to the Indian health scenario, the toxicological and clinical data requirement may be abbreviated / deferred or omitted as deemed appropriate by the licensing authority.&amp;rdquo;&lt;br /&gt;&lt;br /&gt;The panel report had said, GSK had not conducted the mandatory Phase III trials (involving safety and efficacy trials on patients) on the drug.&lt;br /&gt;&lt;br /&gt;Reacting to a similar observation on its Colistimethate and Pirfenidone by the panel, Cipla said, it followed procedures outlined by the law and there has been no violation. &amp;ldquo;As per the law, it is not mandatory to carry out Phase III trials in India for each and every new drug. Both the drugs in question are marketed in a number of countries internationally and have been proven to be life saving. We deny that there has been any collusion with the DCGI,&amp;rdquo; the company said.&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 14960,
	&#039;title&#039; =&gt; &#039;Drug cos lay onus of medicine approvals at DCGI door-step&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu Business Line&lt;br /&gt;
&lt;br /&gt;
The onus of granting approvals to medicines marketed in the country is on the regulator Drug Controller General of India (DCGI), say drug companies, adding that they have adhered to the law of the land.&lt;br /&gt;
&lt;br /&gt;
The drug-makers were responding to a Parliamentary panel report on health that severely indicted the drug regulatory authority, besides alleging that &amp;ldquo;invisible hands&amp;rdquo; of drug-makers were involved in getting favourable reports on medicines before they are marketed in India.&lt;br /&gt;
&lt;br /&gt;
Bayer has conducted the mandatory clinical trials for Rivaroxaban (indicated for VTE prophylaxis) in India after getting necessary permission from the DCGI, the company said.&lt;br /&gt;
&lt;br /&gt;
The Parliamentary panel had observed: &amp;ldquo;Three opinions (from Professor of Orthopaedics, All India Institute of Medical Sciences, New Delhi; Consultant at Dayanand Medical College, Ludhiana and Professor of Orthopaedics, St. Johns Medical College, Bangalore) on rivaroxaban (Bayer) a drug for prevention of clotting are merely ditto copies of each other.&amp;rdquo;&lt;br /&gt;
&lt;br /&gt;
Bayer responded that the required data and an application for the indication was submitted to the DCGI. &amp;ldquo;As per practice, the DCGI then seeks advice from experts. Our company does not play any role in selecting these experts or evaluating their opinions. This is entirely an internal process of the DCGI. The experts send their opinion letters to the DCGI directly. The DCGI office then evaluates the experts&amp;rsquo; opinion internally,&amp;rdquo; it added.&lt;br /&gt;
&lt;br /&gt;
GlaxoSmithKline Pharmaceuticals said it had licensed Volibris (ambrisentan), a treatment for pulmonary arterial hypertension (PAH), from Gilead for marketing outside the US. Volibris was approved in Europe (2008) and US (2007), and is available in 43 countries.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;It was evaluated in 400 patients in two pivotal phase III studies, including a range of different ethnicities, to assess its safety and efficacy. The complete global clinical data set was submitted by GSK to regulatory authorities in India in 2009 and Volibris gained marketing approval in India in 2010. Since PAH is a rare disease which is life threatening and debilitating, GSK was granted a local clinical trial waiver in India,&amp;rdquo; the company said.&lt;br /&gt;
&lt;br /&gt;
Further, the company said, the Drugs &amp;amp; Cosmetics Act stated: &amp;ldquo;for drugs indicated in life threatening / serious disease or disease of special relevance to the Indian health scenario, the toxicological and clinical data requirement may be abbreviated / deferred or omitted as deemed appropriate by the licensing authority.&amp;rdquo;&lt;br /&gt;
&lt;br /&gt;
The panel report had said, GSK had not conducted the mandatory Phase III trials (involving safety and efficacy trials on patients) on the drug.&lt;br /&gt;
&lt;br /&gt;
Reacting to a similar observation on its Colistimethate and Pirfenidone by the panel, Cipla said, it followed procedures outlined by the law and there has been no violation. &amp;ldquo;As per the law, it is not mandatory to carry out Phase III trials in India for each and every new drug. Both the drugs in question are marketed in a number of countries internationally and have been proven to be life saving. We deny that there has been any collusion with the DCGI,&amp;rdquo; the company said.
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu Business Line, 11 May, 2012, http://www.thehindubusinessline.com/companies/article3407419.ece&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;drug-cos-lay-onus-of-medicine-approvals-at-dcgi-door-step-15084&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 15084,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 14960
$metaTitle = &#039;LATEST NEWS UPDATES | Drug cos lay onus of medicine approvals at DCGI door-step&#039;
$metaKeywords = &#039;medicines,Health&#039;
$metaDesc = &#039;
-The Hindu Business Line

The onus of granting approvals to medicines marketed in the country is on the regulator Drug Controller General of India (DCGI), say drug companies, adding that they have adhered to the law of the land.

The drug-makers were...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu Business Line&lt;br /&gt;&lt;br /&gt;The onus of granting approvals to medicines marketed in the country is on the regulator Drug Controller General of India (DCGI), say drug companies, adding that they have adhered to the law of the land.&lt;br /&gt;&lt;br /&gt;The drug-makers were responding to a Parliamentary panel report on health that severely indicted the drug regulatory authority, besides alleging that &amp;ldquo;invisible hands&amp;rdquo; of drug-makers were involved in getting favourable reports on medicines before they are marketed in India.&lt;br /&gt;&lt;br /&gt;Bayer has conducted the mandatory clinical trials for Rivaroxaban (indicated for VTE prophylaxis) in India after getting necessary permission from the DCGI, the company said.&lt;br /&gt;&lt;br /&gt;The Parliamentary panel had observed: &amp;ldquo;Three opinions (from Professor of Orthopaedics, All India Institute of Medical Sciences, New Delhi; Consultant at Dayanand Medical College, Ludhiana and Professor of Orthopaedics, St. Johns Medical College, Bangalore) on rivaroxaban (Bayer) a drug for prevention of clotting are merely ditto copies of each other.&amp;rdquo;&lt;br /&gt;&lt;br /&gt;Bayer responded that the required data and an application for the indication was submitted to the DCGI. &amp;ldquo;As per practice, the DCGI then seeks advice from experts. Our company does not play any role in selecting these experts or evaluating their opinions. This is entirely an internal process of the DCGI. The experts send their opinion letters to the DCGI directly. The DCGI office then evaluates the experts&amp;rsquo; opinion internally,&amp;rdquo; it added.&lt;br /&gt;&lt;br /&gt;GlaxoSmithKline Pharmaceuticals said it had licensed Volibris (ambrisentan), a treatment for pulmonary arterial hypertension (PAH), from Gilead for marketing outside the US. Volibris was approved in Europe (2008) and US (2007), and is available in 43 countries.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;It was evaluated in 400 patients in two pivotal phase III studies, including a range of different ethnicities, to assess its safety and efficacy. The complete global clinical data set was submitted by GSK to regulatory authorities in India in 2009 and Volibris gained marketing approval in India in 2010. Since PAH is a rare disease which is life threatening and debilitating, GSK was granted a local clinical trial waiver in India,&amp;rdquo; the company said.&lt;br /&gt;&lt;br /&gt;Further, the company said, the Drugs &amp;amp; Cosmetics Act stated: &amp;ldquo;for drugs indicated in life threatening / serious disease or disease of special relevance to the Indian health scenario, the toxicological and clinical data requirement may be abbreviated / deferred or omitted as deemed appropriate by the licensing authority.&amp;rdquo;&lt;br /&gt;&lt;br /&gt;The panel report had said, GSK had not conducted the mandatory Phase III trials (involving safety and efficacy trials on patients) on the drug.&lt;br /&gt;&lt;br /&gt;Reacting to a similar observation on its Colistimethate and Pirfenidone by the panel, Cipla said, it followed procedures outlined by the law and there has been no violation. &amp;ldquo;As per the law, it is not mandatory to carry out Phase III trials in India for each and every new drug. Both the drugs in question are marketed in a number of countries internationally and have been proven to be life saving. We deny that there has been any collusion with the DCGI,&amp;rdquo; the company said.&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/drug-cos-lay-onus-of-medicine-approvals-at-dcgi-door-step-15084.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Drug cos lay onus of medicine approvals at DCGI door-step | Im4change.org</title>
    <meta name="description" content="
-The Hindu Business Line

The onus of granting approvals to medicines marketed in the country is on the regulator Drug Controller General of India (DCGI), say drug companies, adding that they have adhered to the law of the land.

The drug-makers were..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Drug cos lay onus of medicine approvals at DCGI door-step</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu Business Line<br /><br />The onus of granting approvals to medicines marketed in the country is on the regulator Drug Controller General of India (DCGI), say drug companies, adding that they have adhered to the law of the land.<br /><br />The drug-makers were responding to a Parliamentary panel report on health that severely indicted the drug regulatory authority, besides alleging that &ldquo;invisible hands&rdquo; of drug-makers were involved in getting favourable reports on medicines before they are marketed in India.<br /><br />Bayer has conducted the mandatory clinical trials for Rivaroxaban (indicated for VTE prophylaxis) in India after getting necessary permission from the DCGI, the company said.<br /><br />The Parliamentary panel had observed: &ldquo;Three opinions (from Professor of Orthopaedics, All India Institute of Medical Sciences, New Delhi; Consultant at Dayanand Medical College, Ludhiana and Professor of Orthopaedics, St. Johns Medical College, Bangalore) on rivaroxaban (Bayer) a drug for prevention of clotting are merely ditto copies of each other.&rdquo;<br /><br />Bayer responded that the required data and an application for the indication was submitted to the DCGI. &ldquo;As per practice, the DCGI then seeks advice from experts. Our company does not play any role in selecting these experts or evaluating their opinions. This is entirely an internal process of the DCGI. The experts send their opinion letters to the DCGI directly. The DCGI office then evaluates the experts&rsquo; opinion internally,&rdquo; it added.<br /><br />GlaxoSmithKline Pharmaceuticals said it had licensed Volibris (ambrisentan), a treatment for pulmonary arterial hypertension (PAH), from Gilead for marketing outside the US. Volibris was approved in Europe (2008) and US (2007), and is available in 43 countries.<br /><br />&ldquo;It was evaluated in 400 patients in two pivotal phase III studies, including a range of different ethnicities, to assess its safety and efficacy. The complete global clinical data set was submitted by GSK to regulatory authorities in India in 2009 and Volibris gained marketing approval in India in 2010. Since PAH is a rare disease which is life threatening and debilitating, GSK was granted a local clinical trial waiver in India,&rdquo; the company said.<br /><br />Further, the company said, the Drugs &amp; Cosmetics Act stated: &ldquo;for drugs indicated in life threatening / serious disease or disease of special relevance to the Indian health scenario, the toxicological and clinical data requirement may be abbreviated / deferred or omitted as deemed appropriate by the licensing authority.&rdquo;<br /><br />The panel report had said, GSK had not conducted the mandatory Phase III trials (involving safety and efficacy trials on patients) on the drug.<br /><br />Reacting to a similar observation on its Colistimethate and Pirfenidone by the panel, Cipla said, it followed procedures outlined by the law and there has been no violation. &ldquo;As per the law, it is not mandatory to carry out Phase III trials in India for each and every new drug. Both the drugs in question are marketed in a number of countries internationally and have been proven to be life saving. We deny that there has been any collusion with the DCGI,&rdquo; the company said.</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 14960,
		'title' => 'Drug cos lay onus of medicine approvals at DCGI door-step',
		'subheading' => '',
		'description' => '<div align="justify">
-The Hindu Business Line<br />
<br />
The onus of granting approvals to medicines marketed in the country is on the regulator Drug Controller General of India (DCGI), say drug companies, adding that they have adhered to the law of the land.<br />
<br />
The drug-makers were responding to a Parliamentary panel report on health that severely indicted the drug regulatory authority, besides alleging that &ldquo;invisible hands&rdquo; of drug-makers were involved in getting favourable reports on medicines before they are marketed in India.<br />
<br />
Bayer has conducted the mandatory clinical trials for Rivaroxaban (indicated for VTE prophylaxis) in India after getting necessary permission from the DCGI, the company said.<br />
<br />
The Parliamentary panel had observed: &ldquo;Three opinions (from Professor of Orthopaedics, All India Institute of Medical Sciences, New Delhi; Consultant at Dayanand Medical College, Ludhiana and Professor of Orthopaedics, St. Johns Medical College, Bangalore) on rivaroxaban (Bayer) a drug for prevention of clotting are merely ditto copies of each other.&rdquo;<br />
<br />
Bayer responded that the required data and an application for the indication was submitted to the DCGI. &ldquo;As per practice, the DCGI then seeks advice from experts. Our company does not play any role in selecting these experts or evaluating their opinions. This is entirely an internal process of the DCGI. The experts send their opinion letters to the DCGI directly. The DCGI office then evaluates the experts&rsquo; opinion internally,&rdquo; it added.<br />
<br />
GlaxoSmithKline Pharmaceuticals said it had licensed Volibris (ambrisentan), a treatment for pulmonary arterial hypertension (PAH), from Gilead for marketing outside the US. Volibris was approved in Europe (2008) and US (2007), and is available in 43 countries.<br />
<br />
&ldquo;It was evaluated in 400 patients in two pivotal phase III studies, including a range of different ethnicities, to assess its safety and efficacy. The complete global clinical data set was submitted by GSK to regulatory authorities in India in 2009 and Volibris gained marketing approval in India in 2010. Since PAH is a rare disease which is life threatening and debilitating, GSK was granted a local clinical trial waiver in India,&rdquo; the company said.<br />
<br />
Further, the company said, the Drugs &amp; Cosmetics Act stated: &ldquo;for drugs indicated in life threatening / serious disease or disease of special relevance to the Indian health scenario, the toxicological and clinical data requirement may be abbreviated / deferred or omitted as deemed appropriate by the licensing authority.&rdquo;<br />
<br />
The panel report had said, GSK had not conducted the mandatory Phase III trials (involving safety and efficacy trials on patients) on the drug.<br />
<br />
Reacting to a similar observation on its Colistimethate and Pirfenidone by the panel, Cipla said, it followed procedures outlined by the law and there has been no violation. &ldquo;As per the law, it is not mandatory to carry out Phase III trials in India for each and every new drug. Both the drugs in question are marketed in a number of countries internationally and have been proven to be life saving. We deny that there has been any collusion with the DCGI,&rdquo; the company said.
</div>',
		'credit_writer' => 'The Hindu Business Line, 11 May, 2012, http://www.thehindubusinessline.com/companies/article3407419.ece',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'drug-cos-lay-onus-of-medicine-approvals-at-dcgi-door-step-15084',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 15084,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 14960,
	'metaTitle' => 'LATEST NEWS UPDATES | Drug cos lay onus of medicine approvals at DCGI door-step',
	'metaKeywords' => 'medicines,Health',
	'metaDesc' => '
-The Hindu Business Line

The onus of granting approvals to medicines marketed in the country is on the regulator Drug Controller General of India (DCGI), say drug companies, adding that they have adhered to the law of the land.

The drug-makers were...',
	'disp' => '<div align="justify">-The Hindu Business Line<br /><br />The onus of granting approvals to medicines marketed in the country is on the regulator Drug Controller General of India (DCGI), say drug companies, adding that they have adhered to the law of the land.<br /><br />The drug-makers were responding to a Parliamentary panel report on health that severely indicted the drug regulatory authority, besides alleging that &ldquo;invisible hands&rdquo; of drug-makers were involved in getting favourable reports on medicines before they are marketed in India.<br /><br />Bayer has conducted the mandatory clinical trials for Rivaroxaban (indicated for VTE prophylaxis) in India after getting necessary permission from the DCGI, the company said.<br /><br />The Parliamentary panel had observed: &ldquo;Three opinions (from Professor of Orthopaedics, All India Institute of Medical Sciences, New Delhi; Consultant at Dayanand Medical College, Ludhiana and Professor of Orthopaedics, St. Johns Medical College, Bangalore) on rivaroxaban (Bayer) a drug for prevention of clotting are merely ditto copies of each other.&rdquo;<br /><br />Bayer responded that the required data and an application for the indication was submitted to the DCGI. &ldquo;As per practice, the DCGI then seeks advice from experts. Our company does not play any role in selecting these experts or evaluating their opinions. This is entirely an internal process of the DCGI. The experts send their opinion letters to the DCGI directly. The DCGI office then evaluates the experts&rsquo; opinion internally,&rdquo; it added.<br /><br />GlaxoSmithKline Pharmaceuticals said it had licensed Volibris (ambrisentan), a treatment for pulmonary arterial hypertension (PAH), from Gilead for marketing outside the US. Volibris was approved in Europe (2008) and US (2007), and is available in 43 countries.<br /><br />&ldquo;It was evaluated in 400 patients in two pivotal phase III studies, including a range of different ethnicities, to assess its safety and efficacy. The complete global clinical data set was submitted by GSK to regulatory authorities in India in 2009 and Volibris gained marketing approval in India in 2010. Since PAH is a rare disease which is life threatening and debilitating, GSK was granted a local clinical trial waiver in India,&rdquo; the company said.<br /><br />Further, the company said, the Drugs &amp; Cosmetics Act stated: &ldquo;for drugs indicated in life threatening / serious disease or disease of special relevance to the Indian health scenario, the toxicological and clinical data requirement may be abbreviated / deferred or omitted as deemed appropriate by the licensing authority.&rdquo;<br /><br />The panel report had said, GSK had not conducted the mandatory Phase III trials (involving safety and efficacy trials on patients) on the drug.<br /><br />Reacting to a similar observation on its Colistimethate and Pirfenidone by the panel, Cipla said, it followed procedures outlined by the law and there has been no violation. &ldquo;As per the law, it is not mandatory to carry out Phase III trials in India for each and every new drug. Both the drugs in question are marketed in a number of countries internationally and have been proven to be life saving. We deny that there has been any collusion with the DCGI,&rdquo; the company said.</div>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 14960,
	'title' => 'Drug cos lay onus of medicine approvals at DCGI door-step',
	'subheading' => '',
	'description' => '<div align="justify">
-The Hindu Business Line<br />
<br />
The onus of granting approvals to medicines marketed in the country is on the regulator Drug Controller General of India (DCGI), say drug companies, adding that they have adhered to the law of the land.<br />
<br />
The drug-makers were responding to a Parliamentary panel report on health that severely indicted the drug regulatory authority, besides alleging that &ldquo;invisible hands&rdquo; of drug-makers were involved in getting favourable reports on medicines before they are marketed in India.<br />
<br />
Bayer has conducted the mandatory clinical trials for Rivaroxaban (indicated for VTE prophylaxis) in India after getting necessary permission from the DCGI, the company said.<br />
<br />
The Parliamentary panel had observed: &ldquo;Three opinions (from Professor of Orthopaedics, All India Institute of Medical Sciences, New Delhi; Consultant at Dayanand Medical College, Ludhiana and Professor of Orthopaedics, St. Johns Medical College, Bangalore) on rivaroxaban (Bayer) a drug for prevention of clotting are merely ditto copies of each other.&rdquo;<br />
<br />
Bayer responded that the required data and an application for the indication was submitted to the DCGI. &ldquo;As per practice, the DCGI then seeks advice from experts. Our company does not play any role in selecting these experts or evaluating their opinions. This is entirely an internal process of the DCGI. The experts send their opinion letters to the DCGI directly. The DCGI office then evaluates the experts&rsquo; opinion internally,&rdquo; it added.<br />
<br />
GlaxoSmithKline Pharmaceuticals said it had licensed Volibris (ambrisentan), a treatment for pulmonary arterial hypertension (PAH), from Gilead for marketing outside the US. Volibris was approved in Europe (2008) and US (2007), and is available in 43 countries.<br />
<br />
&ldquo;It was evaluated in 400 patients in two pivotal phase III studies, including a range of different ethnicities, to assess its safety and efficacy. The complete global clinical data set was submitted by GSK to regulatory authorities in India in 2009 and Volibris gained marketing approval in India in 2010. Since PAH is a rare disease which is life threatening and debilitating, GSK was granted a local clinical trial waiver in India,&rdquo; the company said.<br />
<br />
Further, the company said, the Drugs &amp; Cosmetics Act stated: &ldquo;for drugs indicated in life threatening / serious disease or disease of special relevance to the Indian health scenario, the toxicological and clinical data requirement may be abbreviated / deferred or omitted as deemed appropriate by the licensing authority.&rdquo;<br />
<br />
The panel report had said, GSK had not conducted the mandatory Phase III trials (involving safety and efficacy trials on patients) on the drug.<br />
<br />
Reacting to a similar observation on its Colistimethate and Pirfenidone by the panel, Cipla said, it followed procedures outlined by the law and there has been no violation. &ldquo;As per the law, it is not mandatory to carry out Phase III trials in India for each and every new drug. Both the drugs in question are marketed in a number of countries internationally and have been proven to be life saving. We deny that there has been any collusion with the DCGI,&rdquo; the company said.
</div>',
	'credit_writer' => 'The Hindu Business Line, 11 May, 2012, http://www.thehindubusinessline.com/companies/article3407419.ece',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'drug-cos-lay-onus-of-medicine-approvals-at-dcgi-door-step-15084',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 15084,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 14960
$metaTitle = 'LATEST NEWS UPDATES | Drug cos lay onus of medicine approvals at DCGI door-step'
$metaKeywords = 'medicines,Health'
$metaDesc = '
-The Hindu Business Line

The onus of granting approvals to medicines marketed in the country is on the regulator Drug Controller General of India (DCGI), say drug companies, adding that they have adhered to the law of the land.

The drug-makers were...'
$disp = '<div align="justify">-The Hindu Business Line<br /><br />The onus of granting approvals to medicines marketed in the country is on the regulator Drug Controller General of India (DCGI), say drug companies, adding that they have adhered to the law of the land.<br /><br />The drug-makers were responding to a Parliamentary panel report on health that severely indicted the drug regulatory authority, besides alleging that &ldquo;invisible hands&rdquo; of drug-makers were involved in getting favourable reports on medicines before they are marketed in India.<br /><br />Bayer has conducted the mandatory clinical trials for Rivaroxaban (indicated for VTE prophylaxis) in India after getting necessary permission from the DCGI, the company said.<br /><br />The Parliamentary panel had observed: &ldquo;Three opinions (from Professor of Orthopaedics, All India Institute of Medical Sciences, New Delhi; Consultant at Dayanand Medical College, Ludhiana and Professor of Orthopaedics, St. Johns Medical College, Bangalore) on rivaroxaban (Bayer) a drug for prevention of clotting are merely ditto copies of each other.&rdquo;<br /><br />Bayer responded that the required data and an application for the indication was submitted to the DCGI. &ldquo;As per practice, the DCGI then seeks advice from experts. Our company does not play any role in selecting these experts or evaluating their opinions. This is entirely an internal process of the DCGI. The experts send their opinion letters to the DCGI directly. The DCGI office then evaluates the experts&rsquo; opinion internally,&rdquo; it added.<br /><br />GlaxoSmithKline Pharmaceuticals said it had licensed Volibris (ambrisentan), a treatment for pulmonary arterial hypertension (PAH), from Gilead for marketing outside the US. Volibris was approved in Europe (2008) and US (2007), and is available in 43 countries.<br /><br />&ldquo;It was evaluated in 400 patients in two pivotal phase III studies, including a range of different ethnicities, to assess its safety and efficacy. The complete global clinical data set was submitted by GSK to regulatory authorities in India in 2009 and Volibris gained marketing approval in India in 2010. Since PAH is a rare disease which is life threatening and debilitating, GSK was granted a local clinical trial waiver in India,&rdquo; the company said.<br /><br />Further, the company said, the Drugs &amp; Cosmetics Act stated: &ldquo;for drugs indicated in life threatening / serious disease or disease of special relevance to the Indian health scenario, the toxicological and clinical data requirement may be abbreviated / deferred or omitted as deemed appropriate by the licensing authority.&rdquo;<br /><br />The panel report had said, GSK had not conducted the mandatory Phase III trials (involving safety and efficacy trials on patients) on the drug.<br /><br />Reacting to a similar observation on its Colistimethate and Pirfenidone by the panel, Cipla said, it followed procedures outlined by the law and there has been no violation. &ldquo;As per the law, it is not mandatory to carry out Phase III trials in India for each and every new drug. Both the drugs in question are marketed in a number of countries internationally and have been proven to be life saving. We deny that there has been any collusion with the DCGI,&rdquo; the company said.</div>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Drug cos lay onus of medicine approvals at DCGI door-step

-The Hindu Business Line The onus of granting approvals to medicines marketed in the country is on the regulator Drug Controller General of India (DCGI), say drug companies, adding that they have adhered to the law of the land. The drug-makers were responding to a Parliamentary panel report on health that severely indicted the drug regulatory authority, besides alleging that “invisible hands” of drug-makers were involved in getting favourable reports on medicines before they are marketed in India. Bayer has conducted the mandatory clinical trials for Rivaroxaban (indicated for VTE prophylaxis) in India after getting necessary permission from the DCGI, the company said. The Parliamentary panel had observed: “Three opinions (from Professor of Orthopaedics, All India Institute of Medical Sciences, New Delhi; Consultant at Dayanand Medical College, Ludhiana and Professor of Orthopaedics, St. Johns Medical College, Bangalore) on rivaroxaban (Bayer) a drug for prevention of clotting are merely ditto copies of each other.” Bayer responded that the required data and an application for the indication was submitted to the DCGI. “As per practice, the DCGI then seeks advice from experts. Our company does not play any role in selecting these experts or evaluating their opinions. This is entirely an internal process of the DCGI. The experts send their opinion letters to the DCGI directly. The DCGI office then evaluates the experts’ opinion internally,” it added. GlaxoSmithKline Pharmaceuticals said it had licensed Volibris (ambrisentan), a treatment for pulmonary arterial hypertension (PAH), from Gilead for marketing outside the US. Volibris was approved in Europe (2008) and US (2007), and is available in 43 countries. “It was evaluated in 400 patients in two pivotal phase III studies, including a range of different ethnicities, to assess its safety and efficacy. The complete global clinical data set was submitted by GSK to regulatory authorities in India in 2009 and Volibris gained marketing approval in India in 2010. Since PAH is a rare disease which is life threatening and debilitating, GSK was granted a local clinical trial waiver in India,” the company said. Further, the company said, the Drugs & Cosmetics Act stated: “for drugs indicated in life threatening / serious disease or disease of special relevance to the Indian health scenario, the toxicological and clinical data requirement may be abbreviated / deferred or omitted as deemed appropriate by the licensing authority.” The panel report had said, GSK had not conducted the mandatory Phase III trials (involving safety and efficacy trials on patients) on the drug. Reacting to a similar observation on its Colistimethate and Pirfenidone by the panel, Cipla said, it followed procedures outlined by the law and there has been no violation. “As per the law, it is not mandatory to carry out Phase III trials in India for each and every new drug. Both the drugs in question are marketed in a number of countries internationally and have been proven to be life saving. We deny that there has been any collusion with the DCGI,” the company said.